Abemaciclib and Letrozole in Metastatic Male Breast Cancer

IF 1.5 Q4 ONCOLOGY
Cancer reports Pub Date : 2024-11-15 DOI:10.1002/cnr2.70054
Leon Schönfeld, Christian Möhring, Rouven Strobel, Hanns Leonhard Kaatsch, Stephan Waldeck, Ulrike Wagner
{"title":"Abemaciclib and Letrozole in Metastatic Male Breast Cancer","authors":"Leon Schönfeld,&nbsp;Christian Möhring,&nbsp;Rouven Strobel,&nbsp;Hanns Leonhard Kaatsch,&nbsp;Stephan Waldeck,&nbsp;Ulrike Wagner","doi":"10.1002/cnr2.70054","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men. To our knowledge, a therapeutic approach with a combination of letrozole and abemaciclib has not yet been described for a male patient with metastatic breast cancer.</p>\n </section>\n \n <section>\n \n <h3> Case Description</h3>\n \n <p>Here, we report a case of a male patient with advanced metastatic breast cancer treated with a combination of letrozole and abemaciclib. The therapy was well tolerated with no reported side effects. The follow-up CT showed regression of the primary tumor mass and the lymph nodes and soft tissue metastases.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In summary, this case report clearly shows the effectiveness of the therapeutic approach and should be discussed for the treatment of future patients.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 11","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564860/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men. To our knowledge, a therapeutic approach with a combination of letrozole and abemaciclib has not yet been described for a male patient with metastatic breast cancer.

Case Description

Here, we report a case of a male patient with advanced metastatic breast cancer treated with a combination of letrozole and abemaciclib. The therapy was well tolerated with no reported side effects. The follow-up CT showed regression of the primary tumor mass and the lymph nodes and soft tissue metastases.

Conclusion

In summary, this case report clearly shows the effectiveness of the therapeutic approach and should be discussed for the treatment of future patients.

Abstract Image

Abemaciclib 和来曲唑治疗转移性男性乳腺癌。
背景:男性乳腺癌是一种非常罕见的疾病,只占所有乳腺癌的 1%左右。治疗策略以女性乳腺癌的治疗策略为基础。迄今为止,还缺乏随机数据来支持男性的特定治疗方式。据我们所知,来曲唑和阿柏西尼联合治疗转移性乳腺癌男性患者的方法尚未见报道:在此,我们报告了一例男性晚期转移性乳腺癌患者接受来曲唑和阿贝昔单抗联合治疗的病例。患者对治疗的耐受性良好,无任何副作用。随访 CT 显示原发肿瘤肿块、淋巴结和软组织转移灶均已消退:总之,本病例报告清楚地表明了治疗方法的有效性,值得在今后的患者治疗中加以讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer reports
Cancer reports Medicine-Oncology
CiteScore
2.70
自引率
5.90%
发文量
160
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信